Health In Tech reports Monday with mounting short interest and fresh C-suite sales. Short sellers lifted positions 76% over the past month while insiders exited $90k net in the past 90 days.
Short interest stands at 0.77% of free float as of April 23. That's up 0.7% day-over-day and 75.5% over the past month. Days to cover sits at 6.62 on official FINRA data. Cost to borrow is 19.1%, down 2.6% over the past week. Utilisation hit 72%, well below the 52-week high of 100%. The recent climb in shorts follows volatile swings — shares shorted spiked above 500k in late March before pulling back into the 340k range.
No options data available.
Craig-Hallum initiated coverage on April 20 with a Buy rating and $4 target. Analyst George Sutton set the firm's first price point. Maxim Group opened coverage in June 2025 at Buy with a $2.50 target. The mean target of $4.28 implies 183% upside from the $1.51 close. Coverage remains thin with just two firms tracking the stock.
HIT trades at 34.6x earnings, up 8.9 points over the past month. EV/EBITDA sits at 15.0x, down 0.1 points in 30 days. The stock ranks in the 59th percentile on EPS surprise. It sits in the 9th percentile on ORTEX's short score rank and 3rd percentile on utilisation rank. Quality and momentum scores are unavailable.
Insiders sold $90k net over the past 90 days. The CEO offloaded 35,140 shares at $1.50 on April 15. The CFO sold 21,480 shares the same day. Tim Johnson holds 49.7% of shares with a 1 million share increase as of January. Julia Qian added 979k shares to reach 18% ownership as of mid-April. Vanguard increased its stake by 284k shares to 0.98% in Q1.
The company last reported on March 25. Prior prints were also clustered around mid-to-late March 2026.
No active ORTEX Alpha signals.
See the live data behind this article on ORTEX.
Open HIT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
